Nektar Therapeutics (NKTR)

31.13
0.49 1.55
NASDAQ
Prev Close 31.62
Open 31.70
Day Low/High 30.24 / 31.70
52 Wk Low/High 29.22 / 111.36
Volume 1.69M
Exchange NASDAQ
Shares Outstanding 174.10B
Market Cap 5.40B
Div & Yield N.A. (N.A)
Kessler Topaz Meltzer & Check, LLP - Reminds Investors Of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics

Kessler Topaz Meltzer & Check, LLP - Reminds Investors Of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics

The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") on behalf of purchasers of Nektar securities between November 11, 2017...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

NEW YORK, Nov. 8, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRC, ERA, HCI, MRO, PAA, PRPH, QDEL, SRE, TSLA Downgrades: ALRM, APEI, ASH, AVNS, CHUY, CTLT, HCLP, KE, MB, NKTR, NTB, TTWO Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Nektar Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - NKTR

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Nektar Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - NKTR

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc.

Nektar Therapeutics Reports Financial Results For The Third Quarter Of 2018

Nektar Therapeutics Reports Financial Results For The Third Quarter Of 2018

SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018.

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR).

New Clinical Oncology Collaboration Between Nektar And Pfizer To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With Avelumab And Talazoparib Or Enzalutamide In Multiple Cancers

New Clinical Oncology Collaboration Between Nektar And Pfizer To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With Avelumab And Talazoparib Or Enzalutamide In Multiple Cancers

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc.

Nektar Therapeutics To Host Webcast Conference Call With Melanoma Specialists For Analysts & Investors During 2018 Society For Immunotherapy Of Cancer 33rd Annual Meeting

Nektar Therapeutics To Host Webcast Conference Call With Melanoma Specialists For Analysts & Investors During 2018 Society For Immunotherapy Of Cancer 33rd Annual Meeting

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with melanoma specialists and company management on Saturday, November 10, 2018 at 9:00 a.

INVESTOR ACTION REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTOR ACTION REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

NEW YORK, Nov. 2, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR).

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

Scott Scott Attorneys At Law LLP Alerts Investors To Securities Class Action Against Nektar Therapeutics (NKTR)

Scott Scott Attorneys At Law LLP Alerts Investors To Securities Class Action Against Nektar Therapeutics (NKTR)

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period").

Nektar To Announce Financial Results For The Third Quarter 2018 On Wednesday, November 7, 2018, After Close Of U.S.-Based Financial Markets

Nektar To Announce Financial Results For The Third Quarter 2018 On Wednesday, November 7, 2018, After Close Of U.S.-Based Financial Markets

SAN FRANCISCO, Oct. 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018, after the close of U.

Nektar Therapeutics Becomes #47 Most Shorted S&P 500 Component, Replacing Expeditors International Of Washington

Nektar Therapeutics Becomes #47 Most Shorted S&P 500 Component, Replacing Expeditors International Of Washington

The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Behind the Selloff: Cramer's 'Mad Money' Recap (Thursday 10/4/18)

Behind the Selloff: Cramer's 'Mad Money' Recap (Thursday 10/4/18)

Jim Cramer lists the things we need to see before the bear backs off and the market regains its footing.

Anheuser-Busch InBev, Alteryx, Walker & Dunlop: 'Mad Money' Lightning Round

Anheuser-Busch InBev, Alteryx, Walker & Dunlop: 'Mad Money' Lightning Round

Jim Cramer weighs in on Anheuser-Busch InBev, Alteryx, Walker & Dunlop, Kratos Defense & Security, Johnson Controls, Nektar Therapeutics, Align Technology.

The New #48 Most Shorted S&P 500 Component: Nektar Therapeutics

The New #48 Most Shorted S&P 500 Component: Nektar Therapeutics

The most recent short interest data has been released for the 09/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

INVESTOR ALERT: Investigation Of Nektar Therapeutics Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Nektar Therapeutics Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) complied with the federal securities laws.

Stitch Fix Tumbles; Nektar Finally Adds a Woman to Board -- ICYMI

Stitch Fix Tumbles; Nektar Finally Adds a Woman to Board -- ICYMI

Here's what you need to know now for Tuesday, Oct. 2.

U.S.-Canada Trade Deal, Tesla, Women on Company Boards - 5 Things You Must Know

U.S.-Canada Trade Deal, Tesla, Women on Company Boards - 5 Things You Must Know

U.S. stock futures rise sharply after the U.S. reaches an agreement with Canada to revamp the North American Free Trade Agreement; Tesla soars after CEO Elon Musk settles with the SEC; California bill requires women on company boards.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXL, BIG, DK, FOSL, NFG, NKTR, SRC, TGH, UTSI Downgrades: AIRG, AXAS, HPP, PAA, QDEL, RAD Initiations: FND, RETA, TOCA Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics Takes Over #53 Spot From Leggett & Platt

Nektar Therapeutics Takes Over #53 Spot From Leggett & Platt

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #53 spot from Leggett & Platt, Inc. , according to ETF Channel.

Nektar Is the One S&P 500 Company Without a Woman Director

Nektar Is the One S&P 500 Company Without a Woman Director

Nektar Therapeutics remains the only S&P 500 company without a woman on the board, according to BoardEx, a relationship mapping service of TheStreet.

Tech Alone Can't Save the Rally: Cramer's 'Mad Money' Recap (Tuesday 6/5/18)

Tech Alone Can't Save the Rally: Cramer's 'Mad Money' Recap (Tuesday 6/5/18)

Jim Cramer says the tech titans are leading the way, but out side of the tech sector, very few stocks are following.

Hasbro, Dropbox, Carlyle Group: 'Mad Money' Lightning Round

Hasbro, Dropbox, Carlyle Group: 'Mad Money' Lightning Round

Jim Cramer weighs in on Hasbro, Dropbox, Carlyle Group, Corning, Banco Santander, Goldman Sachs, Edwards Lifesciences, J. Jill and more.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics shares got destroyed on Monday. Here is why.

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.

TheStreet Quant Rating: C (Hold)